Buy
Average AnalystBuy
Top AnalystBullish
Stock Target AdvisorStrong Buy
Average UserUSD 140.64
0.00 (0.00%)
USD 20.97B
1.81M
USD 222.29(+58.05%)
Based on the Biogen Inc stock forecast from 27 analysts, the average analyst target price for Biogen Inc is USD 222.29 over the next 12 months. Biogen Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Biogen Inc is Bullish , which is based on 8 positive signals and 2 negative signals. At the last closing, Biogen Inc’s stock price was USD 140.64. Biogen Inc’s stock price has changed by +2.41% over the past week, -2.11% over the past month and -37.02% over the last year.
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
This stock has shown below median revenue growth in the previous 5 years compared to its sector